Genmab A/S shares rise 4.22% premarket after appointing Matt Kiely as General Manager for the UK.

Genmab A/S rose 4.22% in premarket trading, with the company announcing the appointment of Matt Kiely as General Manager for the United Kingdom. This move strengthens Genmab's commercialization capabilities in Europe and prepares the company to bring its innovative antibody-based medicines to more patients. Matt Kiely brings over 20 years of global pharmaceutical leadership, with deep expertise in oncology, market access, and building high-performing organizations.